Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin

@inproceedings{Yang2013InfluenzaAV,
  title={Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin},
  author={Jie Yang and Minmin Li and Xintian Shen and Shuwen Liu},
  booktitle={Viruses},
  year={2013}
}
Influenza A virus (IAV) has caused seasonal influenza epidemics and influenza pandemics, which resulted in serious threat to public health and socioeconomic impacts. Until now, only 5 drugs belong to two categories are used for prophylaxis and treatment of IAV infection. Hemagglutinin (HA), the envelope glycoprotein of IAV, plays a critical role in viral binding, fusion and entry. Therefore, HA is an attractive target for developing anti‑IAV drugs to block the entry step of IAV infection. Here… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Investigational hemagglutinin-targeted influenza virus inhibitors.

Expert opinion on investigational drugs • 2017
View 3 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 87 references

A cell-penetrating helical peptide as a potential HIV-1 inhibitor.

Journal of molecular biology • 2008
View 11 Excerpts
Highly Influenced

Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin.

Annual review of biochemistry • 2000
View 3 Excerpts
Highly Influenced

Antivirals targeting influenza A virus.

Journal of medicinal chemistry • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…